Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | NQO2 | P16083 | 6/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24199471 | 1.00 | MAPT (0.58) | MAPTNQO2MTNR1AMTNR1BRAB9A | |
| SCHEMBL23678344 | 0.91 | MAPT (0.68) | MAPTNQO2MTNR1AMTNR1BRAB9A | |
| SCHEMBL20205809 | 0.91 | MAPT (0.68) | MAPTNQO2MTNR1AMTNR1BRAB9A | |
| SCHEMBL20205940 | 0.82 | HPGD (0.48) | MAPTNQO2MTNR1AMTNR1BRAB9A | |
| SCHEMBL20205543 | 0.81 | MAPT (0.52) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL24199547 | 0.81 | MAPT (0.52) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL23678348 | 0.79 | HPGD (0.48) | MAPTNQO2MTNR1AMTNR1BRAB9A | |
| SCHEMBL24199509 | 0.79 | HPGD (0.48) | MAPTNQO2MTNR1AMTNR1BRAB9A | |
| SCHEMBL15595877 | 0.79 | MAPT (0.59) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL20205815 | 0.77 | SMN1; SMN2 (0.68) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225470-B2 | Tetrazolinone compounds and its use as pest control agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-01-18 | — | — | US | disclosed |
| EP-3544973-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PEST CONTROL AGENTS | SUMITOMO CHEMICAL CO (JP) | 2021-07-28 | — | — | EP | disclosed |
| WO-2018097318-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PEST CONTROL AGENTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225470-B2 | Tetrazolinone compounds and its use as pest control agents | CYC1, MT-CO1, CTRL | MAPT 3767/4885NQO2 4089/4885MTNR1A 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.